Matritech Reaches Agreement with Organon Teknika for Marketing NMP22(R) in Spain and Portugal
NEWTON, Mass., April 20 /PRNewswire/ -- Matritech, Inc., (Nasdaq: NMPS) announced that it hasMatritech Reaches Agreement with Organon Teknika for Marketing NMP22(R) in Spain and Portugal
NEWTON, Mass., April 20 /PRNewswire/ -- Matritech, Inc., (Nasdaq: NMPS) announced that it has reached an agreement on marketing and product purchase terms relating to the Matritech NMP22(R) Test Kit for bladder cancer with the Barcelona-based subsidiary of Organon Teknika for distribution of the product in Spain and Portugal. Organon Teknika is a $484 million healthcare company with significant business in hospital pharmaceuticals and in vitro diagnostics.
"Organon Teknika has large sales forces in Spain, calling on both urologists and diagnostic laboratories," said David L. Corbet, President of Matritech. "We are very excited about their strong marketing capabilities as they relate to selling NMP22 in Spain."
"We wanted a bladder cancer tumor marker to add to our diagnostic portfolio which complements our bladder cancer therapy, BCG. We are extremely pleased to have concluded a distribution agreement for NMP22, which we believe is the best marker available," said Nanno Mees, General Manager of Organon Teknika Espanola, S.A.
The NMP22(R) Test Kit detects a nuclear matrix protein (NMP) found in human epithelial cells. The majority of patients with bladder cancer have been shown to release large quantities of this NMP into their urine. Matritech's Test Kit is an enzyme immunoassay designed to measure the amount of NMP22 in stabilized voided urine. In 1996, the FDA approved the Product for sale in the United States to be used on patients with transitional cell carcinoma (TCC) of the urinary tract.
Matritech, Inc. based in Newton, MA., is using its proprietary NMP technology, discovered at the Massachusetts Institute of Technology (MIT) and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell-, and urine-based diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colon, cervical, breast, and prostate cancer.
Any forward looking statements related to the Company's expectations regarding the performance, benefits to patients, market acceptance and future sales of the Company's existing and future products are subject to a number of risks and uncertainties, many of which are beyond the Company's control. These include but are not limited to, risks related to incorrect use of products by customers, unforeseen delays in FDA and other regulatory approvals, future product demand and pricing, performance of distributors, competitive products and technical developments, health care reform and general business and economic conditions. There can be no assurance that the Company's expectations for its product will be achieved.
SOURCE Matritech, Inc.
CO: Matritech, Inc.
ST: Massachusetts
IN: MTC
SU:
04/20/98 08:36 EDT prnewswire.com
reached an agreement on marketing and product purchase terms relating to the Matritech NMP22(R) Test Kit for bladder cancer with the Barcelona-based subsidiary of Organon Teknika for distribution of the product in Spain and Portugal. Organon Teknika is a $484 million healthcare company with significant business in hospital pharmaceuticals and in vitro diagnostics.
"Organon Teknika has large sales forces in Spain, calling on both urologists and diagnostic laboratories," said David L. Corbet, President of Matritech. "We are very excited about their strong marketing capabilities as they relate to selling NMP22 in Spain."
"We wanted a bladder cancer tumor marker to add to our diagnostic portfolio which complements our bladder cancer therapy, BCG. We are extremely pleased to have concluded a distribution agreement for NMP22, which we believe is the best marker available," said Nanno Mees, General Manager of Organon Teknika Espanola, S.A.
The NMP22(R) Test Kit detects a nuclear matrix protein (NMP) found in human epithelial cells. The majority of patients with bladder cancer have been shown to release large quantities of this NMP into their urine. Matritech's Test Kit is an enzyme immunoassay designed to measure the amount of NMP22 in stabilized voided urine. In 1996, the FDA approved the Product for sale in the United States to be used on patients with transitional cell carcinoma (TCC) of the urinary tract.
Matritech, Inc. based in Newton, MA., is using its proprietary NMP technology, discovered at the Massachusetts Institute of Technology (MIT) and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell-, and urine-based diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colon, cervical, breast, and prostate cancer.
Any forward looking statements related to the Company's expectations regarding the performance, benefits to patients, market acceptance and future sales of the Company's existing and future products are subject to a number of risks and uncertainties, many of which are beyond the Company's control. These include but are not limited to, risks related to incorrect use of products by customers, unforeseen delays in FDA and other regulatory approvals, future product demand and pricing, performance of distributors, competitive products and technical developments, health care reform and general business and economic conditions. There can be no assurance that the Company's expectations for its product will be achieved.
SOURCE Matritech, Inc.
CO: Matritech, Inc.
ST: Massachusetts
IN: MTC
SU:
04/20/98 08:36 EDT prnewswire.com
|
